RxDoctor Payments Data

Yiliam Clavelo

Medical · Sarasota, FLNPI 1851541999

Payments from drug & device makers

$10,323in general payments, 2019–2025

Across 476 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GE HealthCare$590
  • Pfizer$586
  • UCB, Inc.$532
  • Neurocrine Biosciences, Inc.$527
  • Teva Pharmaceuticals USA, Inc.$518
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$390%
  • Food & beverage$10,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,323 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$1,858
Medicare patients
22
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$269,221
NuplazidPimavanserin Tartrate41$202,926
RytaryCarbidopa/Levodopa95$160,449
Aimovig AutoinjectorErenumab-Aooe62$87,547
NeuproRotigotine65$68,528
NourianzIstradefylline13$64,325
GocovriAmantadine Hcl18$64,027
Nurtec OdtRimegepant Sulfate32$60,949
QuliptaAtogepant22$55,150
RexultiBrexpiprazole19$30,528
UbrelvyUbrogepant23$29,864
BotoxOnabotulinumtoxina20$25,719
BriviactBrivaracetam12$19,732
Rasagiline Mesylate44$13,936
Lacosamide70$11,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$527$269,22134 claims
Acadia Pharmaceuticals IncNuplazid$254$202,92641 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$189$163,610109 claims
AbbVieQulipta, Ubrelvy, Botox$2,366$110,73365 claims
UCB, Inc.Neupro, Briviact$532$88,26077 claims
Kyowa Kirin, Inc.Nourianz$168$64,32513 claims
MDD US Operations, LLCGocovri$28$64,02718 claims
PfizerNurtec Odt$586$60,94932 claims
Otsuka America Pharmaceutical, Inc.Rexulti$88$30,52819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →